US 12,215,336 B2
Cell-specific expression of modRNA
Lior Zangi, New York, NY (US); and Ajit Magadum, New York, NY (US)
Assigned to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, NY (US)
Filed by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, NY (US)
Filed on Mar. 28, 2022, as Appl. No. 17/705,609.
Application 17/705,609 is a continuation of application No. 16/354,814, filed on Mar. 15, 2019, granted, now 11,299,749.
Application 16/354,814 is a continuation of application No. PCT/US2017/052035, filed on Sep. 18, 2017.
Claims priority of provisional application 62/395,701, filed on Sep. 16, 2016.
Prior Publication US 2022/0220501 A1, Jul. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/85 (2006.01); A61K 31/7084 (2006.01); A61P 9/10 (2006.01); C12N 5/071 (2010.01); C12N 5/077 (2010.01); C12N 15/113 (2010.01); C12N 15/67 (2006.01)
CPC C12N 15/85 (2013.01) [A61K 31/7084 (2013.01); A61P 9/10 (2018.01); C12N 5/0657 (2013.01); C12N 5/0676 (2013.01); C12N 15/113 (2013.01); C12N 15/67 (2013.01)] 20 Claims
 
1. A method of expressing a protein of interest in a cell, comprising
contacting the cell with a first ribonucleic acid and a second ribonucleic acid, wherein
the first ribonucleic acid comprises a microRNA (miR) recognition element near its 3′UTR that specifically binds an miR expressed in the cell and encodes a translation suppressor protein, and
the second ribonucleic acid comprises a suppressor protein interaction motif that binds the translation suppressor protein and encodes the protein of interest; wherein
one or both of
(a) the first ribonucleic acid comprises the nucleotide sequence of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, and
(b) the second ribonucleic acid comprises the nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8.